Annaida Technologies successfully closed an oversubscribed Pre-Series A funding round to develop its groundbreaking micro-magnetic resonance technology for fertility and life science applications.
Target Information
Annaida Technologies Srl, based in Lausanne, Switzerland, is the world's pioneer in miniaturizing magnetic resonance imaging to a cellular scale. The company has recently completed a successful oversubscribed Pre-Series A funding round to further develop its innovative micro-magnetic resonance platform.
Leading the financing round was HEMEX, alongside participation from existing investors including Zürcher Kantonalbank (ZKB), Excellis, EFI Lake Geneva Ventures, and members of the Investors Club through Simon Fiduciaria. The combined capital raised, augmented by grants from European programs such as EIC Transition (Horizon Europe) and Innosuisse (Swiss Innovation Project), bolsters Annaida's position in preparing its groundbreaking technology for the market.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The fertility industry in Switzerland, and broadly in Europe, has been facing a steady decline in fertility rates, a trend influenced by various social changes
Similar Deals
TiVentures and Claves Investments → InkVivo Technologies
2025
HEMEX
invested in
Annaida Technologies Srl
in 2025
in a Pre-Seed Stage deal